The drug, JSKN003, showed promising early efficacy in colorectal cancer patients in China in a Phase I/II trial.

Intellia disclosed that a patient treated with nexiguran ziclumeran as part of the Phase III MAGNITUDE trial has been hospitalized.

Novartis will acquire the firm's neuroscience assets. Meanwhile, Avidity will separate and transfer its precision cardiology programs to a subsidiary.

In the small first-in-human study, AB-1002 showed an encouraging safety profile and early signs of efficacy, investigators ...

A man with neurofibromas who didn't know he's been clinically diagnosed with NF1, learns he harbors a deeply intronic, likely ...

In the study, researchers molecularly screened nearly 2,000 cancer patients and matched 14 percent into a study arm.

The registrational trial of AD04 could launch as early as mid-2026, if the company is able to shore up necessary funds or ...

In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...

In two Phase I trials, researchers safely administered CAR T cells to high-grade glioma patients and are exploring ways to ...

The company will hold off on making a regulatory decision until it sees results from another trial testing the drug with ...

In a Phase II trial, 23 percent of patients achieved complete remission plus complete remission with partial hematologic recovery on Revuforj.

The firm also said this week it will conduct a pivotal study next year of its PRMT5 inhibitor in MTAP-deleted pancreatic cancer.